Arthur Levin, Ph.D.
Art Levin is a director of Stoke Therapeutics and has a deep track record in the field of nucleic acid-based therapeutics. He currently serves as executive vice president, research and development at Avidity Biosciences. Previously he held the same position at miRagen Therapeutics. Prior to that, Art held senior drug development roles at Ionis Pharmaceuticals and Santaris Pharma. He has played a key role in the development of numerous oligonucleotides, including some of the first approved antisense NDAs. He also helped shape the first microRNA-targeted therapeutic to be used in clinical trials. Art has a combined three decades of experience in all aspects of drug development from discovery through drug registration. He has published more than 60 scientific articles and several of the most cited reviews in the field. He serves as a director of the Oligonucleotide Therapeutics Society and holds several additional scientific organization affiliations and honors. Art received a Ph.D. in toxicology from the University of Rochester and has a B.A. in biology from Muhlenberg College.